LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry Age-Related Macular Degeneration

SEATTLE, June 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry)…

Click here to view original post